A phase 3, randomized, open-label, multi-center clinical study to observe the efficacy and safety of TMX-67 compared to allopurinol in patients with a malignant tumor receiving chemotherapy

Trial Profile

A phase 3, randomized, open-label, multi-center clinical study to observe the efficacy and safety of TMX-67 compared to allopurinol in patients with a malignant tumor receiving chemotherapy

Completed
Phase of Trial: Phase III

Latest Information Update: 24 May 2016

At a glance

  • Drugs Febuxostat (Primary) ; Allopurinol
  • Indications Tumour lysis syndrome
  • Focus Registrational; Therapeutic Use
  • Sponsors Teijin Pharma
  • Most Recent Events

    • 24 Jan 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top